StreetInsider.com News Articles

ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes

Wed, 16 Jul 2025 08:00:00 -0400

LOS ANGELES, July 16, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, announced today that its 2024 Annual Report has been posted to the company’s official website, www.viaderma.com.

Due to the company’s current designation on the OTC Markets Expert Market, financial reports are not permitted to be posted directly to the OTC Markets platform. As part of its ongoing commitment to transparency, ViaDerma is making the Annual Report publicly accessible through its website.

The company

ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes

Wed, 16 Jul 2025 08:00:00 -0400

The company

ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes

Wed, 16 Jul 2025 08:00:00 -0400

The company

ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes

Wed, 16 Jul 2025 08:00:00 -0400

The company

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

Wed, 04 Jun 2025 08:30:00 -0400

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial reports.

The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC Expert Market: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

Wed, 04 Jun 2025 08:30:00 -0400

The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible.

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

Wed, 04 Jun 2025 08:30:00 -0400

The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible.

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

Wed, 04 Jun 2025 08:30:00 -0400

The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible.

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India

Tue, 21 Jan 2025 08:00:00 -0400

LOS ANGELES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, is pleased to announce the opening of a satellite office in Dubai to facilitate its ongoing expansion in the Middle East. Local regulations require businesses to maintain a physical office within the region to conduct commercial operations, making this a strategic move to further ViaDerma's growth and accessibility in the market.

In addition to its Middle Eastern expansion, ViaDerma recently had a productive meeting in Los Angeles with visiting officials

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India

Tue, 21 Jan 2025 08:00:00 -0400

In addition to its Middle Eastern expansion, ViaDerma recently had a productive meeting in Los Angeles with visiting officials

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India

Tue, 21 Jan 2025 08:00:00 -0400

In addition to its Middle Eastern expansion, ViaDerma recently had a productive meeting in Los Angeles with visiting officials

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India

Tue, 21 Jan 2025 08:00:00 -0400

In addition to its Middle Eastern expansion, ViaDerma recently had a productive meeting in Los Angeles with visiting officials

ViaDerma Announces Significant 2024 Achievements and International Expansion

Tue, 10 Dec 2024 08:00:00 -0400

LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, proudly announces the completion of a landmark year marked by significant global expansion and operational milestones. As the company continues its mission to deliver cutting-edge pharmaceutical products to underserved markets, 2024 has proven to be a transformative year.

ViaDerma’s expansion efforts in 2024 have led to a remarkable increase in personnel, with the team now totaling 13 dedicated professionals. This includes 6 employees based in the United States and 7 located abroad, spanning a

ViaDerma Announces Significant 2024 Achievements and International Expansion

Tue, 10 Dec 2024 08:00:00 -0400

ViaDerma Announces Significant 2024 Achievements and International Expansion

Tue, 10 Dec 2024 08:00:00 -0400

ViaDerma Announces Significant 2024 Achievements and International Expansion

Tue, 10 Dec 2024 08:00:00 -0400

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth

Thu, 03 Oct 2024 08:00:00 -0400

LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, announced its financial results for the second quarter and six-month period ending June 30, 2024. The company delivered a strong financial performance with notable revenue consistency, positive net income, and a robust increase in cash reserves.

Financial Highlights for Q2 2024:

Revenue: ViaDerma maintained steady revenues of $300,191 for the first half of 2024, compared to $300,230 for the same period in 2023, showing resilience in its sales despite challenging

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth

Thu, 03 Oct 2024 08:00:00 -0400

Financial Highlights for Q2 2024:

Revenue: ViaDerma maintained steady revenues of $300,191 for the first half of 2024, compared to $300,230 for the same period in 2023, showing resilience in its sales despite challenging

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth

Thu, 03 Oct 2024 08:00:00 -0400

Financial Highlights for Q2 2024:

Revenue: ViaDerma maintained steady revenues of $300,191 for the first half of 2024, compared to $300,230 for the same period in 2023, showing resilience in its sales despite challenging

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth

Thu, 03 Oct 2024 08:00:00 -0400

Financial Highlights for Q2 2024:

Revenue: ViaDerma maintained steady revenues of $300,191 for the first half of 2024, compared to $300,230 for the same period in 2023, showing resilience in its sales despite challenging

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

Tue, 10 Sep 2024 08:00:00 -0400

LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to announce the successful completion of its first shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic to Nigeria. The shipment was sent out as planned before the end of August 2024.

This milestone marks a significant step forward in ViaDerma’s international expansion strategy, as the company continues to meet the growing global demand for its products. The timely execution of this shipment demonstrates

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

Tue, 10 Sep 2024 08:00:00 -0400

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

Tue, 10 Sep 2024 08:00:00 -0400

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

Tue, 10 Sep 2024 08:00:00 -0400

ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria

Tue, 13 Aug 2024 08:00:00 -0400

LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a leader in innovative wound care solutions, is excited to announce that a shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic, has been in production and is being prepared for delivery to Nigeria before the end of August 2024. This marks a significant milestone in ViaDerma’s ongoing efforts to expand its global footprint and provide effective wound care solutions across Africa.

In addition to this shipment, a follow-up delivery is expected in November 2024, ensuring that ViaDerma